Spiriva Respimat is inhaled through a reusable device, with or without food, for long-term control of COPD symptoms. It contains tiotropium, a long-acting bronchodilator that helps keep narrowed…
Spiriva Respimat is inhaled through a reusable device, with or without food, for long-term control of COPD symptoms. It contains tiotropium, a long-acting bronchodilator that helps keep narrowed airways open and supports easier breathing.
Spiriva Respimat is a maintenance inhalation medicine for COPD. Its active ingredient is tiotropium, a long-acting muscarinic antagonist and bronchodilator.
Spiriva Respimat contains tiotropium and is supplied as a solution for inhalation. The stated strength is 2.5 micrograms per actuation. Tiotropium belongs to the long-acting muscarinic antagonist class, also called an antimuscarinic bronchodilator.
Medicine summary
Tiotropium is available in more than one inhaler system. Spiriva Respimat is an inhalation spray, while other tiotropium products may use different devices and instructions. The device determines how the medicine is prepared, inhaled and cleaned.
Regular bronchodilation can make routine activities easier, such as walking, washing or climbing stairs. It may also reduce the burden of daily symptoms and the need for rescue medication in some patients, though it does not remove the underlying lung disease.
The main indication is maintenance treatment for chronic obstructive pulmonary disease, including persistent breathlessness, wheezing and limited airflow. COPD includes conditions such as chronic bronchitis and emphysema. Spiriva helps reduce day-to-day respiratory symptoms, although the amount of improvement differs between patients.[1]
Tiotropium provides long-acting bronchodilation without being an inhaled corticosteroid. Its benefits depend on the pattern of symptoms, lung function, exacerbation history, other illnesses and the patient’s inhaler technique.
Potential benefits include:
GOLD guidance places long-acting bronchodilators within an individualised treatment plan rather than treating one inhaler as suitable for every patient.[3]
Spiriva Respimat is inhaled through a reusable device, with or without food, for long-term control of COPD symptoms. The prescribed regimen for this strength should be confirmed with a healthcare professional before starting. Do not transfer instructions from a tiotropium capsule device to the Respimat inhaler.
Use the Respimat inhaler only with the tiotropium cartridge supplied for that device. The precise regimen for the chosen strength must be confirmed with a healthcare professional before treatment begins.
The mouthpiece should remain clean and dry. Wipe it with a damp cloth or tissue when needed, then allow it to dry fully. Do not submerge the inhaler in water, because moisture can interfere with the device mechanism.
If a dose is missed, do not take extra inhalations to compensate unless a healthcare professional has specifically instructed this. Resume the prescribed schedule and seek advice if repeated missed doses are affecting symptom control.
Tell the prescriber about:
Spiriva should not be used in children unless it has been specifically prescribed for that patient.
Spiriva may not be suitable for you if you have had a reaction to tiotropium, atropine-like medicines or inhaled products, or if you have narrow-angle glaucoma, urinary difficulty, kidney disease, or pregnancy or breastfeeding concerns. Tell your prescriber about other inhalers or medicines with anticholinergic effects before starting treatment.
Dry mouth is a recognised anticholinergic effect of tiotropium. Other possible reactions include throat irritation, cough, constipation, blurred vision, palpitations or difficulty passing urine. The official product information classifies adverse effects by frequency and describes additional uncommon or rare reactions.
| Effect group | Examples and response |
|---|---|
| Common or manageable | Dry mouth, throat irritation or cough; sip water, maintain dental hygiene and discuss persistent symptoms |
| Clinically significant | Constipation, urinary difficulty, blurred vision or eye discomfort; arrange medical review |
| Urgent | Facial swelling, severe wheezing after inhalation, eye pain with coloured halos or inability to pass urine; seek prompt care |
Small, frequent sips of water may ease dry mouth. Sugar-free gum can stimulate saliva, but persistent dryness raises the risk of dental discomfort and should not simply be ignored.
Tiotropium acts mainly in the airways, but anticholinergic effects can occur elsewhere. Blurred vision may be more concerning if the spray reaches the eyes. Wash the eye and seek urgent assessment for eye pain, halos around lights or sudden visual change.
Constipation can become more troublesome in people who already have slow bowel movements. Urinary difficulty deserves prompt attention, especially in men with a history of bladder-outflow problems.
Stop relying on the inhaler as a routine treatment plan and seek urgent care if breathing becomes suddenly worse immediately after inhalation. This may indicate paradoxical bronchospasm, an uncommon reaction in which the airways tighten rather than open.
Urgent assessment is also appropriate for swelling of the lips, tongue or throat, widespread rash, faintness or severe difficulty breathing. These symptoms may indicate a serious allergic reaction.
Tiotropium blocks muscarinic signalling in the smooth muscle surrounding the airways. This reduces the nerve-driven tendency of those muscles to tighten, allowing the bronchial tubes to remain more open.
An anticholinergic medicine reduces the effects of acetylcholine, a nerve-signalling chemical. A bronchodilator relaxes airway muscle and increases the space available for airflow.
M1 and M3 receptors are muscarinic receptors involved in airway nerve signalling. Activation of these receptors can contribute to bronchial muscle contraction and mucus secretion. Tiotropium binds to muscarinic receptors and limits this constricting signal, with prolonged activity in the airways.[2]
The most consequential mistakes are practical rather than pharmacological. They can make a suitable treatment appear ineffective.
The main difference between inhalers is their active ingredient, duration and treatment role. Spiriva contains tiotropium, while Atrovent contains ipratropium. Both are antimuscarinic bronchodilators, but they have different duration and dosing characteristics.
| Inhaler or category | Active ingredient and role |
|---|---|
| Spiriva | Tiotropium; long-acting maintenance bronchodilator for COPD |
| Atrovent | Ipratropium; shorter-acting antimuscarinic bronchodilator |
| Reliever inhaler | Salbutamol, also called albuterol; short-acting beta-agonist for rapid symptom relief |
Atrovent and Spiriva are not interchangeable without clinical direction. A person should not convert one regimen into the other by matching the number of inhalations.
Salbutamol, known internationally as albuterol, relaxes airway muscle through a different receptor pathway and is commonly used as a reliever. Frequent reliance on it can signal poor control, worsening COPD or a technique problem.
Salmeterol with fluticasone is also different. Salmeterol is a long-acting bronchodilator, while fluticasone is an inhaled corticosteroid. That combination may be considered when the clinical profile supports an inhaled corticosteroid, such as selected exacerbation patterns, but it is not a direct equivalent to tiotropium.
In clinical practice, persistent breathlessness does not automatically mean that tiotropium has failed. The first checks often include device technique, regular use, smoking exposure, rescue-inhaler frequency and whether another condition is contributing to the symptoms.
A patient can inhale every planned dose and still receive little medicine if the spray is released after breathing in, rather than during the inhalation. The same problem can occur when the mouthpiece is not sealed properly.
Doctors also review whether symptoms have changed since the treatment was started. Worsening cough, fever, sputum changes, swelling, chest pain or a marked fall in exercise tolerance may require assessment for an exacerbation or another medical problem.
Useful review points include:
The aim is not simply to continue an inhaler indefinitely without review. COPD treatment is adjusted when symptoms, lung function, exacerbation risk or adverse effects change.
A technique demonstration is often more useful than repeating written instructions. Ask a pharmacist, nurse or prescriber to watch the complete process, including device preparation, inhalation speed and breath timing.
The Respimat device produces a fine aerosol. Breathing in too forcefully can reduce coordination, while failing to breathe in during actuation wastes part of the dose.
Do not take extra inhalations to compensate for a missed dose unless a healthcare professional has given that specific instruction. Resume the prescribed regimen and seek advice if missed doses are happening regularly. The EMA product information for tiotropium (2024) supports using the inhaler according to its defined dosing schedule rather than doubling doses.
Spiriva Respimat is inhaled, so food does not determine how the dose reaches the lungs. It can generally be used regardless of meals, provided the prescribed timing is followed. NHS respiratory guidance and the EMA product information from 2024 focus on inhaler technique and regular administration rather than a required meal relationship.
Arrange a clinical review rather than taking extra Spiriva. Poor inhaler technique, ongoing smoking exposure, an exacerbation, disease progression or another cause of breathlessness can explain limited improvement. GOLD guidance used in 2026 supports reassessing symptoms, technique, adherence and exacerbation risk when COPD remains uncontrolled.
A previous serious reaction to tiotropium or a related atropine-like medicine rules out routine use unless a specialist determines otherwise. Narrow-angle glaucoma, urinary retention and significant kidney impairment require specific assessment before treatment. The HPRA product information from 2024 identifies these issues as precautions or contraindication-related concerns for tiotropium inhalation products.[4]
Pulmonary rehabilitation, suitable physical activity and stopping smoking can support COPD management alongside prescribed inhalers. Avoiding smoke exposure and keeping vaccinations up to date may also reduce respiratory stress, although these measures do not replace maintenance treatment. WHO COPD guidance published in 2023 describes physical activity and risk-factor reduction as important parts of long-term respiratory care.[5]
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The long duration of tiotropium allows maintenance treatment through a planned daily regimen. The aim is steadier airway relaxation rather than a quick response to one episode of wheezing.
A common practical problem is expecting a maintenance inhaler to produce an immediate sensation of relief. If symptoms suddenly worsen, use the prescribed reliever plan and seek urgent help when symptoms are severe.
Based on 3 reviews
I had used the inhaler for about four weeks before walking uphill felt less difficult. The dry mouth was annoying during the first fortnight, so I kept water nearby and used sugar-free gum. The improvement was useful, but I still needed my reliever during flare-ups.
About four weeks 10 Nov 2026The first device did not seem to help. A pharmacist watched me use it and noticed I was pressing the button before starting to breathe in. My technique improved after that, although the inhaler did not remove all of my morning wheeze.
15 Oct 2026I used Spiriva for several months and found daily breathing steadier. Constipation became troublesome after another medicine was added, so my prescriber reviewed the full list. The treatment stayed in place, but the other medicine needed attention.
Several months 28 Oct 2026
